Semax
Semax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
FDA Status
Not FDA-approved in US — approved in Russia for stroke and cognitive disorders
Typical Dose
200–600 mcg intranasal, morning
Evidence Grade
BLimited clinical + robust preclinical evidence
Clinics Indexed
89 providers have offered Semax in our tracked directory.
Key Reported Benefits
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Regulatory & Safety Context
FDA status: Not FDA-approved in US — approved in Russia for stroke and cognitive disorders
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.